Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9360088 | 0.83 | HSD11B1 (0.54) | HSD11B1ALDH1A1TSHRTDP1RBP4 | |
| SCHEMBL15150588 | 0.82 | HSD11B1 (0.50) | HSD11B1ALDH1A1TSHRTDP1BCAT2 | |
| SCHEMBL12163513 | 0.82 | HSD11B1 (0.42) | HSD11B1ALDH1A1TSHRTDP1RBP4 | |
| SCHEMBL515098 | 0.82 | KMT2A (0.56) | HSD11B1ALDH1A1MEN1KMT2A | |
| SCHEMBL14349353 | 0.82 | BCAT2 (0.37) | HSD11B1ALDH1A1TSHRTDP1BCAT2 | |
| SCHEMBL16579385 | 0.82 | LOX (0.41) | HSD11B1CA2BCAT2MEN1KMT2A | |
| SCHEMBL20939911 | 0.80 | TDP1 (0.48) | HSD11B1ALDH1A1TSHRTDP1RBP4 | |
| SCHEMBL664385 | 0.79 | TSHR (0.48) | HSD11B1ALDH1A1TSHRTDP1RBP4 | |
| SCHEMBL1095473 | 0.79 | HSD11B1 (0.44) | HSD11B1ALDH1A1TSHRTDP1RBP4 | |
| SCHEMBL2069124 | 0.79 | CA2 (0.52) | HSD11B1ALDH1A1TSHRTDP1RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230136177-A1 | IMMUNOMODULATING O-HET/ARYL AZALIDES | ZOETIS SERVICES LLC | 2023-05-04 | — | — | US | disclosed |
| US-20230136177-A1 | IMMUNOMODULATING O-HET/ARYL AZALIDES | ZOETIS SERVICES LLC | 2023-05-04 | — | — | US | disclosed |
| US-20230028700-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | FU RUI (CA) | 2023-01-26 | — | — | US | disclosed |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-7319097-B2 | Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride | BIOVITRUM AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007044050-A2 | 1H-IMIDAZO[4,5-D]THIENO[3,2-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ACHE, TRPV1, OPRL1 | HSD11B1 1951/4885ALDH1A1 917/4885TSHR 4694/4885 |
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | EGFR, ERBB2, WEE1 | HSD11B1 368/4885ALDH1A1 2834/4885TSHR 1774/4885 |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | HSD11B1 3270/4885ALDH1A1 598/4885TSHR 3538/4885 |
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | HSD11B1 673/4885ALDH1A1 363/4885TSHR 1178/4885 |
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | IFNG, IFNAR1, TYK2 | HSD11B1 2158/4885ALDH1A1 4349/4885TSHR 749/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | HSD11B1 570/4885ALDH1A1 262/4885TSHR 1299/4885 |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | HSD11B1 3270/4885ALDH1A1 598/4885TSHR 3538/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | HSD11B1 570/4885ALDH1A1 262/4885TSHR 1299/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HSD11B1 1857/4885ALDH1A1 4178/4885TSHR 1662/4885 |
| US-20230136177-A1 | IMMUNOMODULATING O-HET/ARYL AZALIDES | IL2, MALT1, IL2RA | HSD11B1 79/4885ALDH1A1 276/4885TSHR 1835/4885 |
| US-20230028700-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | GMPS, GUCY1A2, GUCY1B2 | HSD11B1 1988/4885ALDH1A1 1109/4885TSHR 3125/4885 |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | HSD11B1 1120/4885ALDH1A1 2287/4885TSHR 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.